comprehensive -WSS

comprehensive

author：entertainment 2025-10-01 21:40:30 - browse：2

Illustration of a laptop on top of a TV with a hand sticking out, holding a newspaper. -- coverage from STAT — Adobe

WASHINGTON – If you live in this city, you’re probably awash in pharmacy benefit manager ads — whether you’re listening to an NPR podcast, reading the New York Times, streaming “Yellowstone,” or watching the U.S. Open Golf Championships. It doesn’t matter if it’s 5 a.m., primetime, or 11 p.m.; in between ads for dog joint supplements and the “Barbie” movie, you will inevitably learn about these middlemen of the prescription drug market.

Ads eviscerating and glorifying PBMs have been around for years. But they’ve intensified over the past three months as Congress scrutinizes PBMs’ role in shaping high drug prices. Over a half-dozen U.S. House and Senate Committees have started investigating PBMs, advancing bipartisan legislation to increase transparency in the industry; ban PBMs from charging more for a drug than what they pay (and pocketing the difference); and require them to pass all fees, rebates, and other payments they receive to insurers.

Lobbying groups have responded to this legislative push with dueling campaigns in the court of public opinion. On one side is the Pharmaceutical Care Management Association, the trade association representing PBMs, which argues that pharmaceutical companies are responsible for high drug prices. On the other side is the industry group PhRMA, which points the finger right back, saying that PBMs are really to blame. Both trade associations have launched ad campaigns worth millions of dollars, blanketing TV, radio, social media, print, and beyond.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： 340B reform proposal comes out of Senate working group

leisure time

WSS

Schizophrenia gene found to be linked to cells' energy dysfunction

Why CTE doesn’t keep Americans from enjoying the Super Bowl

YouTube cracks down on misinformation on cancer treatment

Adopting new red light myopia treatments may be short

Timeline: How the deadly wildfires took over Maui day by day

Idaho college killings prosecutors challenge defense's grand jury claims

focus

comprehensive

focus

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Medicare Advantage plans can’t deny care with AI, CMS warns

Walensky prepares to leave CDC — and Congress — behind

What’s missing from the debate over nursing home staff minimums

DIEP, the 'gold standard' of breast reconstruction, is under threat

Montana youths win climate lawsuit against state for promoting fossil fuels

BioMarin wins approval for gene therapy to treat hemophilia A

Bernie brings in new pharma CEOs to talk drug prices

In Memoriam: Notable people who died in 2023

After Optum profits sink, UnitedHealth makes changes

knowledge

Biogen’s boardroom scandal saddles CEO with first crisis

Surgery pushed Ben Carson to fame

Novo Holdings to buy drug manufacturer Catalent in $16.5B deal

Health AI: on the border between health care and tech

Bernie brings in new pharma CEOs to talk drug prices

What to know about the judge who will handle the Trump case

hotspot

Wikipedia

leisure time

hotspot